New clinical trial targets the most common form of skin cancer with a compound based on CNIO discoveries

by CNIO - Centro Nacional de Investigaciones Oncológicas

Highlight Therapeutics and CNIO are collaborating to proof BO-112 effectiveness against the most common form of skin cancer, which is linked to sun exposure and is on the rise.

Read more
Subscribe to Directory
Write an Article

Recent News

¿Por qué no es recomendable llevar la ...

La mejor actitud que podemos adoptar es la de trat...

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Curapath highlights its collaboration wi...

by Curapath

Curapath is pleased to acknowledge the significant progress achieved b...

Photos Stream